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Abstract 
Microencapsulation of pancreatic islets for the treatment of Type I Diabetes Mellitus (T1DM) generates a 
high quantity of empty microcapsules, resulting in high therapeutic graft volumes that can enhance the host’s 
immune response. We report a 3D printed microfluidic magnetic sorting device for microcapsules 
purification with the objective to reduce the number of empty microcapsules prior transplantation. In this 
study, INS1E pseudoislets were microencapsulated within alginate (A) and alginate-poly-L-lysine-alginate 
(APA) microcapsules and purified through the microfluidic device. APA microcapsules demonstrated higher 
mechanical integrity and stability than A microcapsules, showing better pseudoislets viability and biological 
function. Importantly, we obtained a reduction of the graft volume of 77.5% for A microcapsules and 78.6% 
for APA microcapsules. After subcutaneous implantation of induced diabetic Wistar rats with magnetically 
purified APA microencapsulated pseudoislets, blood glucose levels were restored into normoglycemia 
(<200 mg/dL) for almost 17 weeks. In conclusion, our described microfluidic magnetic sorting device 
represents a great alternative approach for the graft volume reduction of microencapsulated pseudoislets and 
its application in T1DM disease. 
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Type 1 Diabetes Mellitus (T1DM) is a metabolic disorder characterized by the autoimmune 
destruction of the pancreatic β-cells and, subsequently, an absolute deficiency of insulin to 
maintain blood-glucose homeostasis (de Groot et al., 2004, Yun Lee et al., 2007). Currently, 
exogenous insulin injection is widely implemented being the most effective therapy. However, 
administration of insulin is onerous for the patients, since it is difficult for these formulations to 
avoid both hyperglycemia and hypoglycemia episodes, which can lead to diabetic complications 
(Skrzypek et al., 2017, Li et al., 2014). Alternatively, the Edmonton protocol emerged as a 
promising method to restore the endogenous β-cell function, thus, normalizing the glucose 
metabolic control in patients with T1DM (Street et al., 2004). This procedure is based on the 
transplantation of isolated cadaveric pancreatic islets, thus providing a new β-cell source capable 
of assessing blood-glucose levels and secrete insulin in a glucose-dependent manner in T1DM 
patients. Although great successes have been achieved in the glucose homeostasis restoration, 
there are still several issues to overcome before the widespread clinical application. One of the 
main obstacle of islet transplantation is the long-term use of immunosuppressants to avoid the 
immune rejection of transplanted islets (Ryan et al., 2001, Ryan et al., 2002, Li et al., 2014). In 
order to circumvent this problem, pancreatic islets can be immunoisolated by microencapsulation 
techniques within a biocompatible matrix (El-Sherbiny and Yacoub, 2013, de Vos and Marchetti, 
2002). 
 
The microencapsulation technology provides a physical barrier between the therapeutic cells 
and the host immune system, thus avoiding the entrance of high molecular weight immune 
components such as immunoglobulins and immune cells (El-Sherbiny and Yacoub, 2013). 
Moreover, the structure of the microcapsule permits the diffusion of nutrients and oxygen between 
the environment and the core of the microcapsule, while allowing the release of the therapeutic 
molecules produced by the embedded cells, as for example, insulin (Yang and Yoon, 2015). 
Among different biomaterials, such as poly(hydroxyethyl methacrylate-methyl methacrylate), 
agarose, chitosan, and polyethylene glycol (PEG); alginate is the most commonly used biomaterial 
in pancreatic islet microencapsulation (Borg and Bonifacio, 2011). This natural polymer has 
excellent properties for biomedical applications as it demonstrates high biocompatibility and low 
toxicity (Lee and Mooney, 2011, Sakata et al., 2012). Moreover, alginate microcapsules can be 
modified to tune their physical properties, like their mechanical and diffusion properties, which are 
critical to ensure their integrity and to allow the release of therapeutic molecules produced by the 
encapsulated cells, respectively (Smidsrod and Skjak-Braek, 1990, Strand et al., 2001). However, 
this technology has several technical obstacles that difficult its clinical application. One crucial 
problem is the high number of empty microcapsules generated during the islet microencapsulation 
process, leading to a high graft volume, which can enhance the host immune reaction after 
implantation (Kobayashi et al., 2006). Although the reduction of the graft volume is nowadays still 
being accomplished by separating the microencapsulated islets from the empty microcapsules by 
hand selection, the manual procedure is tedious, slow, and complicates its reproducibility (Buder 
et al., 2013, King, 2001, Park et al., 2017, Chen et al., 2012). On this regard, many microfluidic 
techniques for cell sorting have been proposed over the last decade, including active and passive 
sorting; the former being mostly employed (Wyatt Shields et al., 2015, Xi et al., 2017). Active 
sorting can be categorized, according to the actuation mechanism, as electric, acoustic, magnetic, 
pneumatic and thermal sorting (Adeyemi, 2017, Myklatun et al., 2017, Girault et al., 2017, Wyatt 
Shields et al., 2015). Among all, magnetic actuation is the most commonly used method in many 
applications (Wyatt Shields et al., 2015, Xi et al., 2017). Different applications in which magnetic 
separation techniques and microfluidic devices have been implemented, in macro or mesoscale 
systems, including the extraction and concentration of magnetized porcine pancreatic islets from 
the digested pancreas that are previously magnetized in vivo (Kennedy et al., 2007), or the 
microencapsulation of pancreatic islets or other cells within microfluidic devices (Tendulkar et al., 
2012). However, this application has not been used yet for the magnetic purification of magnetized 
microencapsulated islets from empty microcapsules. Overall, microfluidics systems constitute 
microscale platforms that enable the automatization and monitorization of the purification process. 
Importantly, these systems also minimize technical errors improving the reproducibility of the 
purification process. Moreover, as described by Temiz et al., the 3D printing technology enables 
the fabrication of complex microfluidic devices in a single-step, and allows the prototyping and 
low volume production of monolithic LOC devices for microfluidic applications, that do not 
require an additional sealing or microfluidic port integration step (Temiz et al., 2015). This 
facilitates the design conformation for the inlet/outlet connectors, as well as the integration of 
other external components (e.g., magnets) with no need of any external packaging. Furthermore, 
3D printing enables easy modifications of design features, accelerating the optimization stage of 
the microfluidic performance. 
 
In this manuscript, with the aim of reducing the therapeutic graft volume in T1DM, we report a 
3D printed magnetic sorting microfluidic device for the purification of microencapsulated 
pseudoislets. To this end, we combined the superparamagnetic iron oxide nanoparticles (SPIONs) 
and the microfluidic technologies. On the one hand, SPIONs provide magnetic properties to the 
pseudoislet-containing microcapsules that allow their separation, and, on the other hand, 
microfluidics offers the creation of a platform at microscale level that enables the purification 
process, its automatization and monitorization. For the validation of the device, we generated a 
pancreatic islet-like cell aggregates from the INS1E rat insulinoma cell line. After purifying the 
microencapsulated pseudoislets through the microfluidic device, different parameters were 
evaluated in vitro such as the viability, metabolic activity, insulin production and mechanical 
integrity of the purified and non-purified microcapsules. Then, the therapeutic potential of purified 
microencapsulated rat pancreatic pseudoislets was investigated in Wistar rats with induced T1DM. 
2. Materials and methods 
2.1. Materials and reagents 
Ultrapure low-viscosity high guluronic acid sodium alginate (G/M ratio ≥ 1.5) with a molecular 
weight of 75–200 kDa was purchased from FMC Biopolymer (Sandvika, Norway), 
penicillin/streptomycin/glutamine (P/S/G) from Invitrogen (Carlsbad, United States), HEPES 
buffer from Lonza (Basilea, Switzerland), trisodium citrate dihydrate and sodium chloride (NaCl) 
from Panreac (Castellar del Vallès, Spain), and Rat Insulin ELISA kit from Mercodia (Uppsala, 
Sweden). Poly-L-lysine hydrobromide (PLL, 15–30 kDa), poly(ethyleneimine) solution (PEI), 
sodium pyruvate, β-mercaptoethanol, citric acid solution, the Cell Counting Kit 8 (CCK-8), 
potassium chloride (KCl), magnesium chloride (MgCl2), calcium chloride (CaCl2), bovine serum 
albumin (BSA), streptozotocin (STZ) and D-glucose were purchased from Sigma-Aldrich (San 
Luis, United States). Dulbecco’s Modified Eagle’s Medium (DMEM), Roswell Park Memorial 
Institute (RPMI) medium 1640, fetal bovine serum (FBS), penicillin–streptomycin (P/S) and 
LIVE/DEAD® Viability/Cytotoxicity Kit were purchased from Life Technologies (Carlsbad, 
United States). 
2.2. Cell culture and INS1E pseudoislets formation 
D1 mouse mesenchymal stem cells (D1-MSCs) (ATCC, USA) and engineered D1-MSCs to 
express the green fluorescence protein (GFP) (D1-MSCs-GFP) were grown in DMEM high 
glucose medium supplemented with 10% FBS and 1% of P/S as previously described (Megías et 
al., 2017). Rat insulinoma INS1E cells provided by the University of Geneva Medical Center 
(Merglen et al., 2004), were cultured in complete medium consisting of RPMI 1640 supplemented 
with 10% FBS, 1% P/S/G, 1% sodium pyruvate 100 mM, 1 M HEPES buffer and 0.1% 
mercaptoethanol. The INS1E cell line was used for pseudoislets formation by the hanging-drop 
method. Briefly, cells were trypsinized to obtain a cell suspension of 2.5 × 10
4
 cells/mL, and 20 µL 
droplets, containing 500 cells/droplet, were applied onto the lid of a 245 × 245 mm cell culture 
dish (Corning Incorporated, New York, United States). The lid was carefully flipped and placed 
onto the dish, which had been previously filled with distilled water to maintain humidity. Cells 
were cultured for five days to allow pseudoislet formation. Next, pseudoislets were harvested and 
transferred into a non-adherent 60 mm culture dish (Corning Incorporated, New York, United 
States). All cells and pseudoislets were cultured in a humidified atmosphere containing 5% CO2 at 
37 °C. 
2.3. Synthesis of SPIONs and cell magnetization 
The SPIONs used in this study were nanoparticles (NPs) of Fe3O4/PEI that were prepared by 
chemical co-precipitation as described by Muñoz de Escalona et al. (2016). Briefly, Fe3O4 NPs 
were re-dispersed in a 0.1 N citric acid solution, sonicated for 40 min and, finally, the dispersion 
was adjusted to pH 7 with 0.5 M NaOH. After that, SPIONs were coated by adding a PEI aqueous 
solution drop-wise to the iron oxide aqueous dispersion (3:4 ratio of PEI:Fe3O4) under mechanical 
stirring (2000 rpm). Then, the dispersion was neutralized again to pH 7 with 0.5 M HCl, and the 
NPs were magnetically washed by repeated separation from the liquid medium by a permanent 
0.4 T magnet. Finally, NPs were resuspended in distilled water. 
 
D1-MSCs-GFP were magnetized as described by Megías et al. (2017). Briefly, NPs were 
diluted in complete culture medium and 10 mL added to a confluent T75 flask at a 11 µg of 
NPs/10
5
 cells ratio. Then, the flask was placed onto a 0.4 T magnet for 15 min. Next, cells were 
detached and microencapsulated. On the other hand, INS1E pseudoislets in suspension were 
placed in a 60 mm culture dish with complete medium containing optimal NPs concentration and 
incubated for 24 h to magnetize the pseudoislets. 
2.4. Microencapsulation 
For microencapsulation, sterile 1.5% (w/v) sodium alginate solution was prepared in a 1% 
(w/v) mannitol solution. Then, it was filtered through a 0.22 µm pore Minisart Syringe Filter 
(Sartorius, Gotinga, Germany). Afterward, cells were suspended in the alginate solution at a cell 
density of 5 × 10
6
 cells/mL or 2000 pseudoislets/mL. These suspensions were extruded in an 
electrostatic droplet generator (Nisco Engineering, Duluth, United States) through a 0.17 mm inner 
diameter needle using a 10 mL sterile syringe with a peristaltic pump at 5.9 mL/h flow rate. 
Microcapsules were collected in a 55 mM CaCl2 bath and maintained in agitation for 10 min to 
obtain the alginate (A) microcapsules. Next, microcapsules were chemically crosslinked with 
0.05% (w/v) PLL for 5 min, and then, they were coated with 0.1% (w/v) alginate for 5 min, giving 
rise to alginate-poly-L-lysine-alginate (APA) microcapsules. All procedures were performed at 
room temperature, under aseptic conditions. Microcapsules were cultured in the correspondent 
complete medium at 37 °C in a 5% CO2 atmosphere. 
2.5. Fabrication of the cell sorting microfluidic device 
The magnetic purification device was designed using PTC Creo Parametric 3D modeling 
Software and manufactured in a Formlab stereolithography 3D printer (Formlabs, Somerville, 
United States) using an optically clear acrylic material, Clear resin FLGP CL02 (Formlabs, 
Somerville, United States), and a 50 µm printing resolution. The printed parts were rinsed in an 
isopropanol bath for 4 min to eliminate the excess of uncured resin, and subsequently, post-cured 
under 365 nm UV light for 15 min to ensure complete polymerization and reach the highest 
strength and stability for the parts. Supports were removed using a snip, and the parts were gently 
sand polished to assure transparent and high-quality polymeric parts. Finally, the chip was 
finalized by covering the top channel with a pressure sensitive PSA AR-MH-92712 adhesive 
(Adhesive Research, Limerick, Ireland). Fig. 2a exhibits the finalized microfluidic magnetic cell 
sorting device for purification of the magnetized-microcapsules. The device integrates commercial 
neodymium magnets of 1.3 T (Supermagnete, Gottmadingen, Germany) with a magnetic clamping 
force of 10.8 N for the 5 mm × 5 mm magnet, and 6.86 N for the 5 mm diameter × 3 mm height 
magnet. Thereby, while the magnetized capsules are envisioned to move to the upper channel due 
to the magnetic field, the empty capsules will be divided equally between both channels, leading to 
a separation of non-magnetized capsules that allows recovery of highly concentrated magnetized 
samples in the upper outlet. 
2.6. Setup for microfluidic microcapsules sorting 
The characterization of microcapsules purification was carried out with A microencapsulated 
non-magnetized D1-MSCs (non-mag-D1-MSCs) and magnetized D1-MSCs-GFP (mag-D1-MSCs-
GFP). Both types of microcapsules were mixed at different mag-D1-MSCs-GFP/non-mag-D1-
MSCs ratios (5/95, 10/90, 25/75, 50/50, 75/25) to evaluate the purification performance at each 
condition. The setup for the characterization of the purification involved: (1) a positive pressure 
flow controller (Fluigent MFCS
TM
 FLEX) to drive the liquid through the microfluidic device; (2) a 
microscope and (3) a fluorescent reader (FluoroReader®, Elveflow) to analyze the distribution of 
the mag-D1-MSCs-GFP microcapsules in situ (Fig. 1a). Fluorescence at the outlet of the channels 
was displayed in real time in order to monitor the deviation of mag-D1-MSCs-GFP from the 
purification channel. Additionally, the purification efficiency for different conditions was 
quantified by flow cytometry. Briefly, non-purified and purified microcapsules from each 
condition were dissolved in 1% trisodium citrate dihydrate. Then, cells were collected by 
centrifugation, rinsed with DPBS, and transferred to a FACS tube. The proportion of mag-D1-
MSCs-GFP and non-mag-D1-MSCs after purification was analyzed for all samples using the BD 
FACS Calibur flow cytometer (BD Bioscience, Franklin Lakes, United States). Three independent 




Fig. 1. (a) Experimental setup for the optimization of microfluidic magnetic cell sorting flow conditions comprised of a 
positive pressure flow controller (1), a microscope with an integrated camera (2) and a fluorescent reader (3). (b) 
Experimental setup for microfluidic magnetic purification of INS1E, in sterile conditions, comprised of a positive pressure 
flow controller (1) and a microscope with an integrated camera (2). 
The purification of A and APA microencapsulated INS1E pseudoislets was carried out under 
sterile conditions by placing the setup within a laminar flow cabinet after ethanol and UV light 
sterilization. The setup was similar than the one used in the separation of non-mag-D1-MSCs and 
mag-D1-MSCs-GFP; but instead of a fluorescent reader, a microscope with an integrated camera 
(ISH500 Tucsen Photonics) and a TCapture software application (ISCapture, Tucsen Photonics) 
were used for real-time monitorization of the purification process (Fig. 1b). 
  
Also, the purification efficiency after separation was determined by measuring the 24 h 
secreted insulin from the non-purified and purified samples. Briefly, 50 μL of microcapsules from 
each sample were rinsed twice with medium, resuspended in 0.5 mL of medium, and incubated for 
24 h at 37 °C and 5% CO2. The insulin content of collected supernatants was quantified with the 
Rat Insulin ELISA kit following the manufacturer’s recommendations. Three independent 
experiments, with three replicates each one, were conducted. 
2.7. Cell metabolic activity and viability determination 
Metabolic activity was determined using the Cell Counting Kit 8 (CCK-8). During the 
optimization of the pseudoislets magnetization process, 50 magnetized pseudoislets were harvest 
after 24 h of incubation with different NPs concentrations (5, 10, 20, 40, 80, 160, 320 and 640 µg 
of NPs/mL), and resuspended in 500 µL of complete medium containing 50 µL of CCK-8 reagent, 
placed in a 500 µL conical tube and incubated in a shaker for 4 h at 37 °C into the incubator. The 
supernatants were collected, transferred into a 96 well-plate, and the absorbance was read out on 
an Infinite M200 TECAN plate reader (TECAN Trading AG, Männedorf, Switzerland) at 450 nm 
with a reference wavelength set at 650 nm. Control tests were carried out similarly incubating the 
pseudoislets in complete medium without NPs. Three independent tests were conducted for each 
condition. 
 
To study the metabolic activity of the purified microencapsulated pseudoislets, 50 µL of 
microcapsules were resuspended in 150 µL of complete medium with 15 µL of CCK-8 reagent, 
plated in a 96-well plate, incubated, and the absorbance was read following the same procedure 
previously described. Non-purified encapsulated pseudoislets were used as controls. Three 
independent tests were conducted for each condition. 
 
On the other hand, cell viability was determined by fluorescence microscopy, and structural 
integrity of the microcapsules was determined by bright field microscopy. With this aim, 25 µL of 
purified encapsulated pseudoislets were stained with the LIVE/DEAD® Viability/Cytotoxicity 
Kit. First, the microcapsules were washed twice with DPBS. Then, they were resuspended in 
200 µL of 0.5 µM calcein AM, and 0.5 µM ethidium homodimer-1 in DPBS and, finally, 
microcapsules were transferred into 96-well plates and incubated at room temperature for 40 min 
in the dark. Next, samples were observed under a Nikon TMS microscope with the 
excitation/emission settings for calcein AM staining (495/515 nm) and ethidium homodimer 
staining (495/635 nm). The images of fluorescence and brightfield microscopy were acquired with 
a Nikon Eclipse TE2000-Scamera (Nikon, Amsterdam, Netherlands), which was controlled by the 
EclipseNet software version 1.20.0, and at least three independent experiments were analyzed. 
2.8. Glucose-stimulated insulin secretion 
In order to assess the microencapsulated pseudoislets insulin secretory capacity, the Glucose-
Stimulated Insulin Secretion assay (GSIS) was performed 24 h after magnetic purification. 50 µL 
of purified and non-purified microcapsules were washed four times with Krebs-Ringer bicarbonate 
(KRB) buffer composed of 125 mM NaCl, 3 mM KCl, 0.85 mM CaCl2, 1.3 mM MgCl2, 0.1% BSA 
and 25 mM HEPES buffer. After washing, microcapsules were incubated at 37 °C in the incubator 
in KRB buffer for 1 h with shaking. Next, KRB buffer was replaced with KRB containing 3.3 mM 
glucose and incubated for 2 h (low glucose condition). Supernatants were collected, and the 
samples were washed with KRB four times again. Next, they were incubated for 2 h in KRB 
containing 16.6 mM glucose (high glucose condition), and supernatants were collected. 
  
The insulin secretion for 24 h from culture supernatants was determined at days 1, 7, 21 and 28 
after magnetic separation. At each timepoint, 50 μL of microcapsules were rinsed twice with 
medium, resuspended in 0.5 mL of medium, and incubated for 24 h at 37 °C and 5% CO2. Then, 
supernatants were collected. The insulin content of collected supernatants was quantified with the 
Rat Insulin ELISA kit following the manufacturer’s recommendations. Three independent 
experiments, with three replicates each one, were conducted. 
2.9. Induction of diabetes in vivo and implantation of pseudoislets-containing microcapsules 
Male Wistar rats of 150–200 g from ENVIGO (Sant Feliu de Codines, Spain) were housed 
with sterile food and autoclaved water. Six days before implantation of microencapsulated 
pseudoislets, diabetes was induced by a single intravenous injection of 80 mg/kg body weight of 
STZ diluted in 50 mM sodium citrate buffer. Animals were considered diabetic if blood glucose 
exceeded 20 mmol/L (>360 mg/dL) for at least two consecutive measurements. Then, diabetic rats 
were divided into 4 groups. The first group was implanted subcutaneously with 0.4 mL from the 
purified microcapsules pool, containing 3000 microencapsulated equivalent pseudoislets/rat, 
suspended in 1 mL PBS using an 18- gauge catheter; the second group was implanted with the 
same volume of microcapsules from the non-purified pool; the third group received the same 
volume of empty microcapsules (without cells), and in the fourth group (negative control) diabetic 
animals were not implanted. Non-diabetic rats were monitored in parallel as controls of glycemia 
too. During implantation, animals were maintained under anesthesia by isoflurane inhalation. 
Blood samples were collected from the tail vein to measure blood glucose levels with a glucometer 
(Abbott Laboratories, Chicago, United States), during the first week every 24 h and afterward, 
weekly. Animals were also weighted daily during the first week after implantation, then twice per 
week and, at the end of the study, weekly. All the experimental procedures were performed in 
compliance with protocols approved by the institutional animal care and use committee of the 
University of Basque Country UPV/EHU (Permit Number: M20_2016_082_CIRIZA ASTRAIN). 
2.10. Glucose tolerance test 
A glucose tolerance test (GTT) was performed two months after microcapsules implantation. A 
dose of 2 g glucose/kg bodyweight was administered intraperitoneally to rats after 12 h fasting, and 
blood glucose levels were measured at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5 6 and 7 h after glucose 
challenge using a glucometer. 
2.11. Immunohistochemistry 
Animals from each group were sacrificed by CO2 inhalation and, the implants were retrieved 
and fixed with 4% formaldehyde (Panreac, Castellar del Vallès, Spain) for histological analyses. 
Serial horizontal cryostat sections (14 μm) were processed for hematoxylin and eosin or Masson’s 
trichrome (H&E) staining. Photographic images were taken using a Nikon D-60. Microscopy 
sections were examined by an expert pathologist blinded to the treatments. The presence and 
distribution of infiltrating cells, and preservation of the tissue along with the extension of fibrosis 
were evaluated. 
  
2.12. Statistical analysis 
Statistical analysis was performed with SPSS software, version 21.00.1. Data were expressed 
as means ± standard deviation, and differences were considered significant for comparison of 
groups using ANOVA, Tukey’s Post Hoc Test when p < 0.05 after assessing their normal 
distribution. Kaplan-Meier cumulative survival analysis was used to determine the animal survival 
of each group of study after transplantation. 
3. Results and discussion 
3.1. Optimization of microfluidic device design and flow conditions for microcapsules purification 
The microfluidic pathway within the device consisted in a “Y” shape configuration, a main 
channel 36 mm long which split in two channels 37 mm long. The design integrated commercial 
neodymium magnets located in parallel to the main channel close to the bifurcation in order to 
trigger the movement of the magnetized capsules to the upper channel due to the magnetic field. 
The empty capsules were expected to be divided equally between both channels, leading to a 
separation of non-magnetized capsules that allows recovery of highly concentrated magnetized 




Fig. 2. (a) 3D printed microfluidic chip sealed with a pressure sensitive adhesive, integrating commercial magnets. The 
chip has been filled with green-colored solution to highlight the internal channels. (b) Working principle of the magnetic 
separation of the microcapsules: while the magnetized-microcapsules move to the upper channel due to the force generated 
by the magnet, the empty capsules divide equally between both channels. (For interpretation of the references to colour in 
this figure legend, the reader is referred to the web version of this article.) 
For setting up the magnetic sorting device and the purification performance, D1-MSCs-GFP 
cells were magnetized (mag-D1-MSCs-GFP), while D1-MSCs cells were not magnetized (non-
mag-D1-MSCs), next generating microcapsules from both populations, representing microcapsules 
containing islets and empty microcapsules. 
 
Different parameters were studied, such as distinct device architectures and magnet 
configurations. Variations on the microfluidic channel dimensions and the position of the 
connectors for the inlet and outlet tubings were analyzed, as well as the magnets configuration, the 
use of different fluid pressure conditions and distinct microcapsules concentrations. Initially, the 
connectors and tubings were arranged perpendicularly to the main microfluidic channel (Fig. 3a), 
which resulted in changes in the direction of the flow due to elbows inside the microchannels, that 
influenced on the local resistance and generated sudden local velocity decrease, decelerating and 
accumulating the microcapsules at a certain point, and causing clogging issues. This problem was 
resolved when the connectors were arranged in parallel to the main fluidic channel (Fig. 3b). 
Similar effects were observed by Li et al. (2011), who investigated the flow performance of a cell 
suspension near the chip inlet area and compared the different performances when using vertical 
and parallel inlet connectors. Vertical inlet connectors comprised larger dead volumes and initial 
impact driven by the vertical direction of hydrodynamic force, resulting in flow irregularities near 
the inlet area and formation of cell blockages, which is especially detrimental to experiments that 
require recovery of purified cells. In contrast, parallel inlets alleviated channel blockage caused by 
large dead volume and irregular flow directions (Li et al., 2011). The parallel configuration of the 
connectors was possible due to the fabrication flexibility provided by the 3D printing technique in 
comparison with more traditional fabrication techniques to generate microfluidic devices such as 




Fig. 3. Optimization of the design and architecture of the magnetic separation device. (a) Image of a microfluidic sorting 
device prototype with perpendicular inlets and outlets connectors clogged by microcapsules. (b) Final 3D printed 
microfluidic sorting device with the optimal inlets and outlets connectors design, magnets positioning and configuration 
avoiding microcapsules clogging. Black arrows: microcapsules clogging the microchannel. 
Regarding the dimensions of the microchannels, the best flow containing microcapsules 
through the microfluidic device, with no clogging issues, was obtained when using the main 
channel of 1 mm × 1 mm cross-section, which splits in two channels of 750 µm × 750 µm cross 
section (Table 1). In this way, alginate microcapsules with an average diameter of 450 µm were 
satisfactorily driven through the microchannels. In addition, a balance between the magnetic field 
and the flow velocity inside the microchannels was essential to provide a high-throughput 
purification system and increase the purification efficiency and yield. Different shapes and number 
of magnets were analyzed for various fluidic pressures (Table 1). On the one hand, employing 
inappropriate balances of too high magnetic forces and too low fluid velocities, in general, led to 
the retention of the magnetized microcapsules near the bifurcation of the split channels, clogging 
the outlet channel and the whole purification. On the other hand, low magnetic forces required low 
flow rates to ensure successful separation of magnetized microcapsules, but this led to a reduced 
movement of the microcapsules after the bifurcation, clogging the microchannels. For this reason, 
the optimal configuration consisted of three magnets; two with rectangular shape 
(5 mm × 5 mm × 5 mm) and a smaller circular magnet (5 mm diameter and 3 mm height), 
generating a total magnetic clamping force of around 28.5 N. For this magnetic force, fluid 
velocities at 50, 60, and 75 mbar fluidic pressures, led to the retention of the magnetized 
microcapsules near bifurcation of the split channels, while higher fluidic pressures (200 mbar) 
resulted in accumulation of the capsules in the constriction of the outlet channels, again clogging 
the whole microfluidic system, resulting 100 mbar the optimal fluidic pressure. 






   
Main channel: 700 µm × 700 µm 
Bifurcated channels: 
575 µm × 575 µm 
✓ Channels clogged due to a high ratio of the particle to the channel 
size 
Main channel: 1 mm × 1 mm 
Bifurcated channels: 
750 µm × 750 µm 
✓ Appropriate particle to channel size ratio 
Inlet/outlet connectors conformation Purification 
result 
Comments 
Vertical connectors ✕ Clogging of the channels near inlet and outlet connectors 
Parallel connectors ✓ – 







    
5 × 5 × 5 mm (3 units) 
 
50–100 ✕ Too high magnetic force for the employed flow 
rates. Retention of microcapsules near magnets, 
leading to clogging. 
200 ✕ Too high flow rate. Clogging occurs in the 
constriction of the outlet channels 
10 × 3.5 × 2.25 mm (1 unit) 
 
50–60 ✕ Appropriate separation of microcapsules, but too 
low flow rates. Clogging in bifurcated channels. 
75–100 ✕ Poor balance between magnetic force and flow rate. 
High loss of magnetized microcapsules 
5 × 5 × 5 mm (2 units) D = 5 mm, 
H = 3 mm (1 unit) 
 
50–75 ✕ Too low flow rate, occasionally clogging occurs 
100 ✓ Successful purification Optimal ratio of magnetic 
force to flow rate 
200 ✕ Too high flow rate. Clogging occurs in the 
construction of the outlet channels 
    
 
  
When the design of the microfluidic device was optimized, we proceeded to optimize the 
particle concentration for its purification through the device. According to Dresaire et al., the 
clogging dynamic is controlled by the concentration of large particles and the flow rate in the 
channel. In case of high flow rates, for example, clogging of a channel can be caused by the 
simultaneous arrival of particles that plug the cross-section of the channel, typically at the 
inlet/outlet or at a constriction. The clogging probability increases with the particle concentration, 
with the flow rate and with the ratio of the particle to the channel size (Dressaire and Sauret, 
2016). 
 
Different microcapsules suspensions were prepared diluting different amounts of 
microcapsules suspensions in 30 mL of cell culture media. Dilutions of 5, 2, 1, 0.5 mL of 









 microcapsules/mL respectively. Those samples were 
processed through the microfluidic device and then analyzed. Microcapsules concentrations higher 
than 93·10
3
 microcapsules/mL resulted in the accumulation of microcapsules in the inlets of the 
microfluidic device, thus blocking the sample flow. However, at 1/30 and 0.5/30 mL of 
microcapsules/mL of media, microcapsules were able to flow through the microfluidic channels 
while the generated magnetic field promoted the separation of the mag-D1-MSCs-GFP from non-
mag-D1-MSCs microcapsules, attracting the mag-D1-MSCs-GFP microcapsules towards the top 
outlet channel, while splitting equally towards both outlet channels the non-mag-D1-MSCs or 
empty microcapsules (Supplementary Material, Video 1 and 2). 
 
Hence, the final microfluidic device design consisted in a main channel of 1 mm × 1 mm cross-
section, which split in two channels of 750 µm × 750 µm cross section where the inlet and outlet 
connectors were arranged in parallel to main fluidic channel; a magnet configuration of three 
magnets strategically placed alongside the main microfluidic channel, two with rectangular shape 
(5 mm × 5 mm × 5 mm) and an smaller circular magnet (5 mm diameter and 3 mm height) placed 
near the bifurcation; and using a pressure of 100 mbar imposed across the whole system, which 
generated a flow rate of 1.3 mL/min with a microcapsules dilution of 1 mL of 
microcapsules/30 mL of media. 
3.2. Characterization of the magnetic purification performance 
Once the optimal device design and working conditions were determined, the performance of 
the purification system depending on the ratio of the magnetized microcapsules respect to the non-
magnetized was studied. Different mag-D1-MSCs-GFP/non-mag-D1-MSCs ratios were evaluated 
(5/95, 10/90, 25/75, 50/50, 75/25) with special attention to the lower ratios 5/95 and 10/90, which 
are similar to the pancreatic islets-containing microcapsules/empty microcapsules proportion after 
microencapsulation of real islets in preclinical studies. 
 
First, the green fluorescence from mag-D1-MSCs-GFP microcapsules at the outlet of the 
channels was displayed, in situ and in real-time, monitoring the loss of magnetized-microcapsules 
that diverted from the purification channel. The fluorescent readouts from both outlet channels 
showed that most of the mag-D1-MSCs-GFP microcapsules were attracted towards the magnets 
and driven through the top channel (Fig. 4a), and a few of them were diverted towards the bottom 





Fig. 4. Optimization of the purification flow conditions for the microfluidic magnetic cell sorting, using mag- D1-MSCs-
GFP and non-Mag-D1-MSCs microcapsules. (a) Fluorescent readouts obtained for the top and, (b) bottom outlet tubings. 
(c) Flow cytometry analysis of non-purified and purified microcapsules from different samples mixtures at different mag-
D1-MSCs-GFP/non-mag-D1-MSCs ratios. (d) Flow cytometry analysis of the non-purified and purified microcapsules 
after 3cycles through the sorting device, for a sample with a 5/95 mag-D1-MSCs-GFP/non-mag-D1-MSCs ratio. 
Second, the non-purified samples and the purified microcapsules collected from the magnet 
channel were quantified by flow cytometry, for each concentration ratio, in order to determine the 
efficiency of the purification. Flow cytometry results showed that, after the purification, the 
concentration of the mag-D1-MSCs-GFP microcapsules increased for all the suspensions isolated 
from the top channel in comparison with the non-purified samples (Fig. 4c). The increase in the 
mag-D1-MSCs-GFP concentration in the different mag-D1-MSCs-GFP/non-mag-D1-MSCs ratios 
relies on the elimination of the non-mag-D1-MSCs microcapsules during the purification step. 
Thereby, the concentration of the mag-D1-MSCs-GFP microcapsules was highly increased for the 
lowest ratios, due to a larger amount of empty microcapsules, achieving an increase of mag-D1-
MSCs-GFP percentage from 5.1 ± 0.36% to 8.6 ± 1.02%, which supposed a purification yield of 
80 ± 7.1% for the 5/95 ratio sample. In contrast, the concentration increase was not so prominent 
for high initial ratios, obtaining a purification yield of 33.3 ± 3.95% for the 75/25 ratio sample. 
 
Finally, a sample with an initial ratio of 5/95 mag-D1-MSCs-GFP / non-mag-D1-MSCs 
microcapsules, envisioned to mimic a real scenario of pancreatic islets-containing microcapsules 
together with a huge number of empty microcapsules, was successively circularized three times 
through the magnetic sorting device. The mag-D1-MSCs-GFP concentration was considerably 
increased, from 5.14 ± 1.01% to 35.23 ± 3.4%, thus obtaining a highly concentrated mag-D1-
MSCs-GFP microcapsules pool with 6.91 ± 0.55 times more presence of mag-GFP-D1-MSCs in 
the purified sample compared to the non-purified sample (Fig. 4d). Therefore, in this case, a 
theoretical implantation volume of 10 mL on microcapsules could be reduced 6.91 times to a final 
implantation volume of 1.48 mL, which would mean an implantation volume reduction of 85.2%. 
3.3. Determination of the optimal conditions for pseudoislets magnetization 
The preservation of pseudoislet viability and the conferring of magnetic motion after 
magnetization are crucial factors for future in vivo studies and clinical applications. For that 
reason, we evaluated the toxic and motion effect of Fe3O4/PEI NPs concentration on INS1E 
pseudoislets after magnetization. To that end, pseudoislets were exposed to different Fe3O4/PEI 
NPs concentrations (0, 5, 10, 20, 40, 80, 160, 320 and 640 µg/mL) for 24 h. No significant 
influence on pseudoislet metabolic activity was detected after exposing to 5, 10, 20, 40 and 80 µg 
Fe3O4/PEI NPs/mL conditions, compared to non-magnetized pseudoislets used as controls (Fig. 5). 
However, at higher concentrations, a dose-dependent cytotoxicity was observed with a significant 
reduction in the metabolic activity of pseudoislets of 30.9% for 160 µg Fe3O4/PEI NPs/mL, 80.6% 
for 320 µg Fe3O4/PEI NPs/mL and, 87.5% for 640 µg Fe3O4/PEI NPs/mL (p < 0.001). Cell 
viability of different cell types, such as A3 human T lymphocytes and Sprague-Dawley rat smooth 
muscle cells, are also not affected after 24 h incubation at low magnetic NPs concentrations (5–
100 µg magnetic NPs/mL), with reduced viability at higher concentrations (Ying and Hwang, 
2010, Zhang et al., 2008). Hence, due to this detected dose-dependent cytotoxicity, higher 




Fig. 5. Metabolic activity of INS1E pseudoislets after incubation with different concentrations of Fe3O4/PEI nanoparticles 
for 24 h. Values represent mean ± SD. ***:p < 0.001 compared to control incubated without Fe3O4/PEI nanoparticles. 
The magnetic NPs concentration used in the magnetization step should be enough to give the 
pseudoislets sufficient magnetic properties to allow the displacement of the microcapsules during 
the purification process. Using 40 and 80 µg Fe3O4/PEI NPs/mL, appropriate magnetic properties 
were provided to pseudoislets, since motion was detected when a magnetic field was applied, by 
placing a magnet next to the petri dish, with higher mobility of the pseudoislets that had been 
incubated with 80 µg Fe3O4/PEI NPs/mL. Likewise, in other studies, porcine pancreatic islets have 
been magnetized with 100 µg magnetic NPs/mL without affecting their viability and being 
magnetically directed as desired when a magnetic field was applied. Also, they had been imaged 
and tracked when implanted in vivo by magnetic resonance imaging (RMI) (Kennedy et al., 2007, 
Kim et al., 2010). In our studies, both 40 and 80 µg Fe3O4/PEI NPs/mL concentrations were able 
to confer magnetic motion to the pseudoislets. However, after microencapsulation, the magnetized 
pseudoislets should be able to displace the whole microcapsule through the microfluidic device 
towards the magnetic channel. Regarding the biosafety of the use of SPIONs, it is well known that, 
at appropriate concentrations, they do not display cytotoxic effects; besides, magnetic 
nanoparticles are metabolized in the lysosomes after intracellular uptake and used in the 
production of hemoglobin and transferrin becoming part of the normal iron metabolism pathway 
of the body (Thakor et al., 2016). Therefore, in our approach, the magnetic nanoparticles inside the 
microcapsules will not have any contact with the surrounding tissue at the implantation site and 
will be metabolized by the encapsulated pseudoislets, thereby ensuring great biosafety. 
 
Overall, since the 80 µg Fe3O4/PEI NPs/mL concentration demonstrated to provide higher 
mobility to the pseudoislets, this concentration was chosen for the subsequent pseudoislets 
magnetization and purification processes. 
3.4. In vitro evaluation of microencapsulated pseudoislets after microfluidic purification 
Two different types of microcapsules for encapsulated magnetized pseudoislets were studied: 
alginate microcapsules (A) and alginate-poly-L-lysine-alginate (APA) microcapsules. Both types 
of microcapsules display different key physical properties, mechanical strength, and 
macromolecules diffusion, which are crucial for the microcapsules integrity during the magnetic 
sorting and the pseudoislet insulin release after purification. A microcapsules provide higher 
diffusion rates than APA microcapsules, since the PLL coating reduce the porosity of the 
microcapsule surface, thus potentially affecting the diffusion of the therapeutic molecules secreted 
by the microencapsulated cells such as insulin. However, the PLL coating in APA microcapsules 
confers higher mechanical strength (Shen et al., 2009, Wilson et al., 2014), a crucial characteristic 
that they need to fulfill in order to avoid their breakage during the high mechanical stress 
generated in the magnetic purification process. Hence, A microcapsules are good candidates for 
pseudoislets microencapsulation in terms of better insulin diffusion, while APA microcapsules are 
good candidates in terms of higher mechanical stability. 
 
After pseudoislets microencapsulation at a density of 2000 pseudoislets/mL of alginate, we 
performed the magnetic purification with three recircularization steps, collecting microcapsules 
from the magnetic channel (purified microcapsules). Samples from the non-purified and purified 
microcapsules were evaluated under the brightfield microscope (Fig. 6a–b). Many empty 
microcapsules were observed in the non-purified sample (Fig. 6a), with a higher presence of 
microencapsulated pseudoislets in the purified sample (Fig. 6b). It was evidenced that the 
pseudoislets featured the expected magnetic properties and enabled the motion of the 
microcapsules towards the magnets placed on the microfluidic device, allowing their purification. 
Besides, microcapsules endured the mechanical stress suffered during the purification process, 





Fig. 6. (a) Representative brightfield microphotographs of microencapsulated pseudoislets directly after encapsulation 
(Non-purified microcapsules) and (b) after 3 recircularized magnetic separations (Purified microcapsules). (c) Glucose-
stimulated insulin secretion of A and APA microencapsulated INS1E pseudoislets before and after 3 recircularized 
magnetic separations. Values represent mean ± SD. ***:p < 0.001 compared to low glucose condition. 
Next, the biological function of A and APA microencapsulated pseudoislets after purification 
was analyzed. For this purpose, the insulin secretory response to glucose challenges was evaluated 
after exposing non-purified and purified A and APA microcapsules to low and high glucose 
concentrations (3.3 mM and 16.7 mM, respectively) (Fig. 6c). For the non-purified samples, 
insulin levels were almost below the lower detection limit, and no significant differences were 
observed between low and high glucose conditions, probably due to the very low presence of 
microencapsulated pseudoislets. However, purified A and APA samples showed higher insulin 
levels. These results evidenced the capacity of both types of microcapsules for insulin production 
and release. Regarding the glucose responsiveness of the encapsulated pseudoislets, the secretion 
of insulin at high-glucose stimulus increased significantly compared to low-glucose stimulus 
(p < 0.001) both in A and APA purified samples (Fig. 5c), with similar insulin folding between 
high and low conditions: 2.52 ± 0.52 and 2,71 ± 0.16 times more insulin secreted in high glucose 
than in low glucose conditions, for A and APA microcapsules, respectively. Therefore, purified 
Fe3O4/PEI NPs-conjugated pseudoislets maintained their capacity to secrete insulin as well as the 
glucose responsiveness within both A and APA microcapsules after the purification process. 
  
We also quantified the insulin secretion from purified and non-purified A and APA 
microcapsules over the time, which allowed to estimate the purification efficiency just after 
purifying and assess the evolution of insulin production over time for 28 days. The insulin 
secretion ratio (purified/non-purified samples) of each time point were compared between A and 
APA microencapsulated pseudoislets (Fig. 7a). Comparing these ratios, at day 1, similar insulin 
folding for A and APA microcapsules were obtained, 4.43 ± 0.59 and 4.67 ± 0.9 respectively, 
which entails a volume reduction of 77.5% for A microcapsules and, 78.6% for APA 
microcapsules with respect to each non-purified sample. The values for APA microcapsules 
remained stable with average insulin secretion ratio values between 4.2 and 4.6 during the length 
of the study, but the insulin ratio from A microcapsules decreased during the first three weeks 
compared to APA microcapsules; from initial average insulin ratios of 4.4 to final values of 3.2. 
Comparing both groups, we detected statistically significant differences at the end of the study, 
when the ratio values from A microcapsules were lower than those from APA microcapsules 
(p < 0.01, at day 20, and p < 0.05, at day 28). These differences between purified/non-purified A 
and APA microcapsules insulin ratios correlated with their metabolic activity, where purified A 
microcapsules showed significant lower metabolic activity values at day 28 compared to APA 
microcapsules (p < 0.01) (Fig. 7b). To explain these results, microcapsules physical integrity and 
cell viability of A and APA purified samples were analyzed over time under brightfield and 
fluorescence microscope (Fig. 7c). Pseudoislets from both types of microcapsules showed cell 
death at day 1 on the surface of the pseudoislets due to the mechanical stress suffered during the 
microencapsulation process. The analysis of A microcapsules under brightfield displayed some 
unencapsulated small cell aggregates at day 1, which were more abundant at the end of the study 
(day 21 and 28 after purification). Moreover, the microscopy analysis unveiled that the 
pseudoislets growth inside A microcapsules provoked an excessive internal mechanical stress that 
led to the progressive breakage of these microcapsules. This progressive A microcapsules rupture 
released pseudoislets and, subsequently, the unprotected pseudoislets fragmented into smaller cell 
aggregates due to the mechanical stress when manipulated for microscopy analysis. Increasing 
amounts of fragmented pseudoislets were observed from day 1 till the end of the study. In contrast, 
in APA microcapsules samples, aggregates were not detected in the media; instead, all 
pseudoislets remained microencapsulated and, importantly, no evidence of microcapsules 
breakage was observed all over time. The higher mechanical strength of APA microcapsules, 
therefore, allowed restricting the pseudoislets growth, maintaining the pseudoislets within the 
matrix, thus improving the biosafety of the graft. The reduced mechanical integrity of A 
microcapsules can be attributed to the poor stability of the reversible ionic crosslinking of the 
sodium alginate macromolecules with a divalent ion, such as for example Ca
2+
 ions. In fact, the 
gelled alginate can exchange Ca
2+
 ions with the Na
+
 present in the media, leading to a progressive 
degradation of the alginate hydrogels, which is an interesting property for cell delivery 
applications, where cells are required to escape from the microcapsule (Wilson et al., 2014). In 
contrast, APA microcapsules are protected against osmosis by the PLL coating, which strengthens 
the microcapsule, preventing its swelling and loss of stiffness (Shen et al., 2009, Wilson et al., 
2014). Therefore, the decrease of the purified/non-purified insulin release and metabolic activity 
ratios for the A microcapsules compared to the APA microcapsules might occur due to the 
differences on their mechanical integrity that led to the loss of A microencapsulated pseudoislets. 
Importantly, for in vivo application in T1DM reversal, microcapsules need to hold physical and 
osmotic stress to avoid any cell exposure (Opara et al., 2010, Vaithilingam and Tuch, 2011), since 
the breakage of the microcapsules may trigger the hostś immune rejection against the exposed 
pseudoislets, implying the graft failure. Based on these results, APA microcapsules were selected 





Fig. 7. Purified/non-purified ratios of (a) insulin production and (b) metabolic activity, of A and APA microencapsulated 
INS1E pseudoislets before and after magnetic separation. Values represent mean ± SD: *p < 0.05, **: p < 0.01 and 
***:p < 0.001. (c) Brightfield microphotographs and fluorescence microscopy images of purified A and APA 
microencapsulated INS1E pseudoislets (green fluorescence for live cells and red for dead cells). Red arrows identify 
fragmented INS1E cell aggregates. Scale bar: 100 µm. (For interpretation of the references to colour in this figure legend, 
the reader is referred to the web version of this article.) 
3.5. Normoglycemia restoration of STZ-induced diabetic Wistar rats 
Blood glucose levels of all studied groups (see Section 2.9 for details of animal groups) were 
monitored for 142 days after STZ injection (Fig. 8a). During the first 11 days after implantation of 
0.4 mL of microcapsules from purified, non-purified and empty microcapsules pools, rats from all 
STZ-treated groups remained diabetic, with blood glucose levels between 350 and 500 mg/dL, 
with no significant differences among groups. In contrast, non-diabetic control rats maintained 
their blood glucose levels around 100 mg/dL. During the whole study, rats from the diabetic group 
and those implanted with non-purified microcapsules and empty microcapsules maintained high 
glucose levels, between 400 and 500 mg/dL, with no significant differences among them. 
However, 19 days after implantation, blood glucose levels of rats implanted with purified 
microcapsules significantly decreased, reaching values between 140 and 200 mg/dL, which are 
comprised within the normal glycemic range (<200 mg/dL), very close to the non-diabetic control 
levels. These results correlated with the bodyweight gain and cumulative survival analysis data 
(Fig. 8b–c). Diabetic control animals did not gain weight during the first weeks, begun to show 
discomfort 22 days after implantation and, subsequently, were sacrificed. Similarly, rats implanted 
with non-purified and empty microcapsules did not gain weight during the first weeks either, but 
discomfort appeared later, from day 44 to 66 after implantation. In contrast, rats implanted with 
purified microencapsulated pseudoislets began to gain weight 2 days after implantation, showing 
statistically significant higher body weight values during all the study compared to the rest of the 
diabetic groups (p < 0.001). Non-diabetic control rats also gained weight during the study always 
showing statistically significant higher values than the rats implanted with purified microcapsules 




Fig. 8. Long-term monitoring of blood glucose levels (a) and body weights (b) of STZ-induced diabetic Wistar rats 
implanted with empty microcapsules, non-purified and purified microcapsules containing INS1E pseudoislets. Non-
diabetic and non-implanted diabetic rats were used as controls. (c) Intraperitoneal glucose tolerance test two months after 
microcapsules implantation. (d) Kaplan-Meier analysis of rats from different groups. Dotted red lines identify the 
microcapsules implantation time point. ***:p < 0.001 compared to rats implanted with purified microencapsulated 
pseudoislets. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of 
this article.) 
Focusing on the animals implanted with purified microcapsules, symptoms of graft failure 
were noticed on day 104 after implantation, being the last graft failure on day 136 post 
implantation. Similarly, Albino Oxford (AO) rats implanted with 2–2.5 mL of non-purified APA 
microencapsulated allogeneic Lewis-islets become normoglycemic within 5 days after 
implantation and, remained normoglycemic, with blood glucose levels below 200 mg/dL. 
However, some animals began to show symptoms of graft failure 42 days after implantation (de 
Vos et al., 2003). Therefore, although the initial therapeutic effect of our purified 
microencapsulated pseudoislets was detected later than in the study by de Vos and cols (de Vos et 
al., 2003), our implants demonstrated better results in terms of normoglycemia maintenance. In 
fact, AO rats showed the first symptoms of graft failure just 42 days after implantation, and in our 
study, the first graft failure was detected on day 104. Hence, these data demonstrate that 
implantation of 0.4 mL of purified microencapsulated pseudoislets is able to restore blood glucose 
levels within the normoglycemic range. In contrast, in other studies, implantation volumes of 
microencapsulated allogeneic pancreatic islets have been ranged between 2 and 2.5 mL per animal 
in order to achieve normoglycemia in STZ-induced diabetic AO rats (De Vos et al., 1999, de Vos 
et al., 2003). Therefore, we have achieved blood glucose levels restoration into the normoglycemic 
range with a 5–6.25 times reduction in the implant volume. Undoubtedly, this is a highly relevant 
achievement for reducing the host’s immune response against the graft (King, 2001). 
 
In order to evaluate the capacity of the different animal groups to respond to glucose stimuli, 
we performed a glucose tolerance test two months after implantation (Fig. 8d). As expected, 
results for the diabetic control animals and those implanted with non-purified and empty 
microcapsules showed no response to glucose stimulus, with high blood glucose levels around 
500 mg/dL. In contrast, in rats implanted with purified microcapsules, which showed initial blood 
glucose levels under 200 mg/dL, glucose values increased up to 420–450 mg/dL, smoothly 
decreasing to final values around 200 mg/dL 7 h after the glucose administration. Non-diabetic 
control rats showed a stronger response to glucose stimulus with lower peak values (around 
230 mg/dL), requiring less time for normoglycemic glucose values restoration, which occurred 2 h 
after glucose administration. Similarly to our results, AO rats implanted with microencapsulated 
allogeneic Lewis-islets show higher initial blood glucose levels than non-diabetic control in the 
glucose tolerance test. However, in that study, animals are able to diminish blood glucose levels 
faster than our rats implanted with purified microcapsules (de Vos et al., 2003). This difference 
might be due to graft implantation site. In fact, in type I diabetes mellitus patients, insulin is 
detected faster in the bloodstream when it is administrated through intraperitoneal injection than 
when it is administered subcutaneously, with ranges between 60 and 150 min and 150–300 min, 
respectively (Giacca et al., 1993). This occurs due to the different degree of vascularization of the 
implantation site; the high vascularization of the peritoneal cavity promotes faster insulin 
absorption, while the subcutaneous tissue is not that highly vascularized, limiting the diffusion of 
insulin towards the bloodstream (Burnett et al., 2014, Figliuzzi et al., 2005). This could have been 
the reason why in our subcutaneously implanted rats we noticed a delayed glucose response and 
slower restoration of normoglycemia. Nevertheless, although the implantation of 
microencapsulated islets in the peritoneum cavity has shown faster glucose response in AO rats, 
this location has several disadvantages that make it not suitable for clinical application. One 
important one is that the implantation of microcapsules in this location goes through an invasive 
surgical technique which provokes a strong inflammatory response in the implantation site (De 
Vos et al., 1999, Robitaille et al., 2005). In addition, the high vascularization of the peritoneum 
facilitates the easy access of the host’s immune cells, which transforms the acute inflammatory 
reaction into a chronic process that leads to the graft failure (Robitaille et al., 2005). Finally, in the 
peritoneum, microencapsulated islets are freely floating, which would difficult the removal of the 
whole graft if required, compromising the biosafety of the implant. Unfortunately, this situation 
would force the use of more invasive techniques such as peritoneum lavage (De Vos et al., 1999, 
de Vos et al., 2003). 
 
Lastly, we performed a histological evaluation by hematoxylin and eosin and Masson’s 
trichrome staining in order to examine the retrieved microcapsules and to evaluate the 
inflammatory response (Fig. 9a–b). Collagen-like surrounding tissue was detected, indicating the 
presence of fibrotic tissue in all the samples, with no differences among the different grafts, 
independently of the implanted microcapsules (Fig. 9a). Also, no differences among groups were 
detected on the surrounding inflammatory response with the presence of some infiltrating 
lymphocyte and neutrophil cells. Regarding the microcapsules, in the empty and non-purified 
microcapsules samples, we mainly observed empty microcapsules, while in the purified sample, 
we observed a higher presence of microencapsulated pseudoislets without cell protruding (Fig. 
9b). Importantly, although the purified sample contained higher quantities of pseudoislets, the 
inflammatory response was similar to the empty and non-purified microcapsules samples, since 






Fig. 9. Foreign body reaction analysis of subcutaneously implanted empty microcapsules, non-purified and purified 
microencapsulated INS1E pseudoislets in STZ-induced diabetic Wistar rats. (a) Representative photographic images of 
Masson's trichrome staining of explanted grafts. (b) Representative images of hematoxylin-eosin staining of explanted 
grafts. Scale bars: 100 µm or 500 µm. 
4. Conclusions 
The combination of 3D printing, microfluidics, magnetic sorting, and magnetic cell labeling 
technologies, enabled the production of a magnetic sorting device for the purification of 
magnetically labeled encapsulated pseudoislets. While these implants showed the capacity to 
normalize glucose blood levels in diabetic rats, a considerable reduction of the graft volume has 
been accomplished (higher than 75%), compared to previously reported works. Our microfluidic 
device provides high purification yields, enables the monitorization of the process and avoids 
manual steps, thus, minimizing technical errors and improving the reproducibility of the 
purification process. Moreover, the miniaturized nature of the approach facilitates the 
parallelization of processes, the multiplexing capabilities, and high-throughput screening. 
Therefore, this technology will improve the efficacy of therapeutic strategies that include the use 
of microencapsulated pancreatic islets for the Type 1 Diabetes Mellitus clinical management. In 
this sense, future directions for its widespread clinical application should focus on scaling-up the 
procedure. On this regard, further investigations on the development of a technology that is able to 
perform the microencapsulation and the sorting processes in one single step would suppose a step 
forward in the optimization and reduction of the costs of this approach, bringing this technology 
closer to the clinics. 
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